Bristol's Opdivo boosts kidney cancer survival

The successful outcome means Opdivo is the first so-called immune checkpoint inhibitor drug to show an improvement in overall survival in patients with renal cell carcinoma (RCC), a common type of kidney cancer.09/26/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news